IN8bio Appoints New President and COO
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 09 2026
0mins
Should l Buy INAB?
Source: seekingalpha
- Executive Appointment: IN8bio has promoted Kate Rochlin to president and chief operating officer, effective immediately, recognizing her leadership since serving as COO since December 2021, which reflects the company's confidence in her capabilities.
- Funding Initiative: IN8bio plans to raise up to $40.2 million through an at-the-market private placement, aimed at strengthening its capital structure and providing financial support for future R&D and operations, thereby driving growth in the biopharmaceutical sector.
- Historical Performance Review: Historical financial data for IN8bio indicates robust revenue growth over the past fiscal year, showcasing the company's competitiveness and the sustained demand in the biopharmaceutical market.
- Quant Rating Insight: Seeking Alpha's Quant Rating on IN8bio reveals a positive market outlook for its future performance, potentially attracting more investor interest and enhancing the company's stock price performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INAB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INAB
Wall Street analysts forecast INAB stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.600
Low
36.00
Averages
92.00
High
180.00
Current: 1.600
Low
36.00
Averages
92.00
High
180.00
No data
About INAB
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IN8bio Reports Q1 Loss but Promising Data Ahead
- Earnings Report: IN8bio's Q1 GAAP EPS stands at -$0.26, reflecting a loss; however, the company's advancements in R&D indicate potential growth opportunities moving forward.
- Platform Development: The firm is advancing its next-generation γδ T cell engager platform, with initial animal data expected in 2026, laying the groundwork for future clinical applications.
- Clinical Data Highlights: IN8bio's reported glioblastoma (GBM) data shows approximately a 97% improvement in progression-free survival compared to standard care, indicating significant efficacy of its treatment approach.
- Future Outlook: Updated median overall survival (mOS) data is set to be presented at ASCO 2026, which is expected to further bolster investor confidence in the company's therapeutic potential.
See More
IN8bio Advances γδ T Cell Engager Platform with Promising Data
- Clinical Data Breakthrough: IN8bio's updated clinical trial data from January 2026 reveals that the median progression-free survival (mPFS) for repeat-dose patients is 13.0 months, representing a 97% improvement over the standard-of-care group's 6.6 months, indicating significant therapeutic efficacy and potential for better patient outcomes.
- Survival Improvement: The median overall survival (mOS) for repeat-dose patients currently stands at 17.2 months, surpassing the 13.2 months for the standard treatment group, with several patients remaining progression-free beyond two years, highlighting the long-term efficacy and potential of this therapy.
- R&D Day Event: IN8bio is set to host its R&D Day on May 21, 2026, in New York City, where it will share the latest advancements of its γδ T cell platform, attracting attention from investors and industry experts regarding its innovations in oncology and autoimmune diseases.
- Financial Position Improvement: As of March 31, 2026, IN8bio's cash position was $21.9 million, a significant increase from $11.9 million in the same period last year, reflecting the company's positive progress in financial management and R&D investments.
See More
IN8bio Reports FY Loss and Launches $40.2M Private Placement
- Earnings Miss: IN8bio's FY GAAP EPS of -$4.44 falls short by $1.22, indicating significant challenges in profitability that could undermine investor confidence and negatively impact stock performance.
- Private Placement Announcement: The company has initiated a private placement of up to $40.2 million at-the-market, aimed at bolstering liquidity to support future R&D and operations, reflecting the urgency for funding amid current financial pressures.
- Quant Rating Insights: Seeking Alpha's Quant Rating on IN8bio suggests a cautious market outlook regarding its future performance, which may influence investor decisions and demand for its stock.
- Historical Financial Trends: Historical earnings data for IN8bio reveals a persistent trend of losses, prompting investors to closely monitor the company's potential for long-term profitability improvement to assess future investment risks and returns.
See More
IN8bio Appoints New President and COO
- Executive Appointment: IN8bio has promoted Kate Rochlin to president and chief operating officer, effective immediately, recognizing her leadership since serving as COO since December 2021, which reflects the company's confidence in her capabilities.
- Funding Initiative: IN8bio plans to raise up to $40.2 million through an at-the-market private placement, aimed at strengthening its capital structure and providing financial support for future R&D and operations, thereby driving growth in the biopharmaceutical sector.
- Historical Performance Review: Historical financial data for IN8bio indicates robust revenue growth over the past fiscal year, showcasing the company's competitiveness and the sustained demand in the biopharmaceutical market.
- Quant Rating Insight: Seeking Alpha's Quant Rating on IN8bio reveals a positive market outlook for its future performance, potentially attracting more investor interest and enhancing the company's stock price performance.
See More
IN8bio Appoints Kate Rochlin as President and COO
- Executive Appointment: IN8bio has announced the immediate promotion of Dr. Kate Rochlin to President and Chief Operating Officer, having previously served as COO since December 2021, overseeing company operations and advancing clinical and preclinical pipelines, marking a strategic focus on growth.
- Leadership Enhancement: Dr. Rochlin has been instrumental in advancing IN8bio's clinical programs and T cell engager platform, with her leadership aligning teams across operations, manufacturing, clinical, and research, ensuring critical milestones are met on schedule, thereby enhancing the company's execution capabilities.
- Clinical Progress: Under her leadership, IN8bio's INB-619 project has made significant strides, with preclinical data showing that it achieved complete B cell depletion comparable to approved T cell engagers with minimal adverse effects, highlighting the company's competitive edge in the field of autoimmune diseases.
- Manufacturing Capability Expansion: Dr. Rochlin has also played a key role in developing and expanding IN8bio's clinical manufacturing program, leading analytical, quality, regulatory, and GMP manufacturing teams across multiple Phase 1 and 2 clinical programs in glioblastoma and hematological cancers, ensuring the company's sustained growth in these areas.
See More
IN8bio Unveils Private Placement Funding Initiative
Securities Purchase Agreement: IN8bio, Inc. has finalized a securities purchase agreement to raise approximately $40.2 million through a private placement involving new and existing institutional investors, as well as company directors and officers.
Funding Allocation: The funds from the initial closing, estimated at $20.1 million, will support operations until mid-2027 and facilitate IND-enabling studies for INB-619, along with regulatory efforts for glioblastoma programs INB-200 and INB-400.
Current Stock Performance: INAB's stock is currently trading at $1.36, reflecting a decrease of $0.02 or 1.45 percent on the Nasdaq.
Disclaimer: The views expressed in the article are those of the author and do not necessarily represent the opinions of Nasdaq, Inc.
See More
IN8bio Reports Q1 Loss but Promising Data Ahead
- Earnings Report: IN8bio's Q1 GAAP EPS stands at -$0.26, reflecting a loss; however, the company's advancements in R&D indicate potential growth opportunities moving forward.
- Platform Development: The firm is advancing its next-generation γδ T cell engager platform, with initial animal data expected in 2026, laying the groundwork for future clinical applications.
- Clinical Data Highlights: IN8bio's reported glioblastoma (GBM) data shows approximately a 97% improvement in progression-free survival compared to standard care, indicating significant efficacy of its treatment approach.
- Future Outlook: Updated median overall survival (mOS) data is set to be presented at ASCO 2026, which is expected to further bolster investor confidence in the company's therapeutic potential.
See More
IN8bio Advances γδ T Cell Engager Platform with Promising Data
- Clinical Data Breakthrough: IN8bio's updated clinical trial data from January 2026 reveals that the median progression-free survival (mPFS) for repeat-dose patients is 13.0 months, representing a 97% improvement over the standard-of-care group's 6.6 months, indicating significant therapeutic efficacy and potential for better patient outcomes.
- Survival Improvement: The median overall survival (mOS) for repeat-dose patients currently stands at 17.2 months, surpassing the 13.2 months for the standard treatment group, with several patients remaining progression-free beyond two years, highlighting the long-term efficacy and potential of this therapy.
- R&D Day Event: IN8bio is set to host its R&D Day on May 21, 2026, in New York City, where it will share the latest advancements of its γδ T cell platform, attracting attention from investors and industry experts regarding its innovations in oncology and autoimmune diseases.
- Financial Position Improvement: As of March 31, 2026, IN8bio's cash position was $21.9 million, a significant increase from $11.9 million in the same period last year, reflecting the company's positive progress in financial management and R&D investments.
See More
IN8bio Reports FY Loss and Launches $40.2M Private Placement
- Earnings Miss: IN8bio's FY GAAP EPS of -$4.44 falls short by $1.22, indicating significant challenges in profitability that could undermine investor confidence and negatively impact stock performance.
- Private Placement Announcement: The company has initiated a private placement of up to $40.2 million at-the-market, aimed at bolstering liquidity to support future R&D and operations, reflecting the urgency for funding amid current financial pressures.
- Quant Rating Insights: Seeking Alpha's Quant Rating on IN8bio suggests a cautious market outlook regarding its future performance, which may influence investor decisions and demand for its stock.
- Historical Financial Trends: Historical earnings data for IN8bio reveals a persistent trend of losses, prompting investors to closely monitor the company's potential for long-term profitability improvement to assess future investment risks and returns.
See More
IN8bio Appoints New President and COO
- Executive Appointment: IN8bio has promoted Kate Rochlin to president and chief operating officer, effective immediately, recognizing her leadership since serving as COO since December 2021, which reflects the company's confidence in her capabilities.
- Funding Initiative: IN8bio plans to raise up to $40.2 million through an at-the-market private placement, aimed at strengthening its capital structure and providing financial support for future R&D and operations, thereby driving growth in the biopharmaceutical sector.
- Historical Performance Review: Historical financial data for IN8bio indicates robust revenue growth over the past fiscal year, showcasing the company's competitiveness and the sustained demand in the biopharmaceutical market.
- Quant Rating Insight: Seeking Alpha's Quant Rating on IN8bio reveals a positive market outlook for its future performance, potentially attracting more investor interest and enhancing the company's stock price performance.
See More
IN8bio Appoints Kate Rochlin as President and COO
- Executive Appointment: IN8bio has announced the immediate promotion of Dr. Kate Rochlin to President and Chief Operating Officer, having previously served as COO since December 2021, overseeing company operations and advancing clinical and preclinical pipelines, marking a strategic focus on growth.
- Leadership Enhancement: Dr. Rochlin has been instrumental in advancing IN8bio's clinical programs and T cell engager platform, with her leadership aligning teams across operations, manufacturing, clinical, and research, ensuring critical milestones are met on schedule, thereby enhancing the company's execution capabilities.
- Clinical Progress: Under her leadership, IN8bio's INB-619 project has made significant strides, with preclinical data showing that it achieved complete B cell depletion comparable to approved T cell engagers with minimal adverse effects, highlighting the company's competitive edge in the field of autoimmune diseases.
- Manufacturing Capability Expansion: Dr. Rochlin has also played a key role in developing and expanding IN8bio's clinical manufacturing program, leading analytical, quality, regulatory, and GMP manufacturing teams across multiple Phase 1 and 2 clinical programs in glioblastoma and hematological cancers, ensuring the company's sustained growth in these areas.
See More
IN8bio Unveils Private Placement Funding Initiative
Securities Purchase Agreement: IN8bio, Inc. has finalized a securities purchase agreement to raise approximately $40.2 million through a private placement involving new and existing institutional investors, as well as company directors and officers.
Funding Allocation: The funds from the initial closing, estimated at $20.1 million, will support operations until mid-2027 and facilitate IND-enabling studies for INB-619, along with regulatory efforts for glioblastoma programs INB-200 and INB-400.
Current Stock Performance: INAB's stock is currently trading at $1.36, reflecting a decrease of $0.02 or 1.45 percent on the Nasdaq.
Disclaimer: The views expressed in the article are those of the author and do not necessarily represent the opinions of Nasdaq, Inc.
See More
